Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mitsubishi Tanabe Pharma Corporation
• Collaborator: Vertex Pharmaceuticals Incorporated

Criteria

Inclusion Criteria:

• Patients diagnosed with genotype 1b chronic hepatitis C

• Patients naive to the concomitant medications with interferon

Exclusion Criteria:

• Patients diagnosed with decompensated cirrhosis

• Patients diagnosed with positive HBs(Hepatitis B virus surface) antigen in the test